Inactive Instrument

Audentes Therapeutics, Inc. Stock

US05070R1041

Biotechnology & Medical Research

Latest news : Audentes Therapeutics, Inc.

24-03-14	Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	CI
22-11-07	Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	CI
22-10-20	Taysha Gene Therapies, Inc. announced that it expects to receive $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	CI
20-12-24	Audentes Therapeutics, Inc. Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy	CI
20-08-21	Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy	CI
20-04-21	Audentes Therapeutics, Inc. Appoints Julie Person as Senior Vice President, Human Resources	CI
20-02-18	Audentes Therapeutics, Inc. Plans to Build New Gene Therapy Manufacturing Facility in Sanford, North Carolina	CI
20-01-15	Audentes Therapeutics, Inc. Announces Management Changes	CI
20-01-15	Audentes Therapeutics, Inc. Approves a Change in the Company’s Fiscal Year to End on March 31	CI
20-01-15	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P TMI Index	CI
20-01-15	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Biotechnology Select Industry Index	CI
20-01-15	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Global BMI Index	CI
20-01-14	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Composite Index	CI

More news

Press Releases: Audentes Therapeutics, Inc.

20-01-15	AUDENTES THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
19-12-16	AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm	BU
19-12-16	AUDENTES THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
19-12-03	AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm	PR
19-12-03	AUDENTES THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

News in other languages: Audentes Therapeutics, Inc.

19-12-03	NASDAQ COMPOSITE : Wall Street poursuit son repli, un accord USA-Chine s'éloigne
19-12-03	DOW JONES 30 : Wall Street ouvre dans le rouge, un accord USA-Chine s'éloigne
19-12-03	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
19-12-03	USA-Les valeurs à suivre à Wall Street (actualisé)
19-12-03	Astellas Pharma : Pharmakonzern Astellas kauft für 3 Mrd Dollar US-Gentherapiespezialisten

More news

Managers and Directors: Audentes Therapeutics, Inc.

Manager	Title	Age	Since
Morten Sogaard PSD	President	-	-
Jason Schwartz CTO	Chief Tech/Sci/R&D Officer	-	2022-05-31
David Smethurst LAW	General Counsel	-	2021-07-31

Director	Title	Age	Since
Alan Beggs BRD	Director/Board Member	-	-
Kush Parmar BRD	Director/Board Member	44	2013-06-30

More insiders

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/15/20	Louis Lange	Tender	Director	368,575	0.8037%
1/15/20	Jennifer Jarrett	Issuer sale	Director	53,200	0.1160%
1/15/20	Thomas Soloway	Tender	Chief Financial Officer	407,257	0.8881%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AUDENTES THERAPEUTICS, INC.	-.--%	-0.03%	-	-	2.77B
WUXI APPTEC CO., LTD.	+4.80%	+7.80%	+70.64%	+114.21%	70.07B
ARGENX SE	+17.12%	+12.05%	+54.42%	+86.20%	52.87B
INSMED INCORPORATED	+3.69%	-5.03%	+0.55%	+482.48%	27.02B
WUXI BIOLOGICS (CAYMAN) INC.	+2.26%	+0.65%	+49.19%	+10.30%	23.61B
BIONTECH SE	-1.62%	-0.87%	-18.27%	-18.75%	23.38B
PHARMAESSENTIA CORPORATION	-6.00%	+13.71%	+244.39%	+443.26%	19.43B
GENMAB A/S	+3.80%	+5.25%	+40.50%	-16.41%	18.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.38%	-3.15%	+20.39%	+589.77%	15.85B
EXELIXIS, INC.	+2.13%	-1.27%	+38.48%	+149.00%	12.7B
Average	+2.67%	-2.08%	+55.59%	+204.45%	29.3B
Weighted average by Cap.	+5.06%	-1.14%	+56.49%	+170.47%

Audentes Therapeutics, Inc. Stock

Stocks

US05070R1041

Biotechnology & Medical Research

Latest news : Audentes Therapeutics, Inc.

Press Releases: Audentes Therapeutics, Inc.

News in other languages: Audentes Therapeutics, Inc.

Managers and Directors: Audentes Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile